What are examples of unipotent and multipotent stem cells? More broadly, stem cells have the ability to do two key things. They can make more of themselves through a process called self-renewal. Also, they have the ability to differentiate into other cell types. This latter property is called potency. Taken together this means by definition […]
Clinical utility & examples of unipotent vs. multipotent stem cells Read More »
I get a lot of questions about stem cells for ALS and more recently people have been specifically interested in NurOwn from BrainStorm Cell Therapeutics. Recently, the FDA denied BrainStorm’s request for a BLA for NurOwn. The company felt its Phase III trial was encouraging. It sounds like they will move forward with a follow-up
Weekly reads: NurOwn, key gene screen, MS, Croce mess Read More »
I get great questions from readers of The Niche including, “Are there multiple ways to get stem cells?” The answer is “yes.” Why is this important? The different sources of stem cells can impact both their use in basic research and their potential clinically. My goal in today’s post is to give an overview of
Digging into the multiple ways to get stem cells Read More »
When I first started The Niche more than a dozen years ago, I hoped we’d see a Parkinson’s disease stem cell therapy by now. A proven one. I was a little too optimistic back then. Now in 2022, I know much better how hard translation to the bedside can be in general. Still, I’m hopeful.
Parkinson’s disease stem cell therapy research update Read More »
It’s always great to read about stem cell clinical trials that are looking encouraging. Stem cell clinical trials Proving a new therapy is safe and effective is so challenging. Remarkably, there are more than 9,300 stem cell clinical trials listed for a “stem cell” search on Clinicaltrials.gov. Of course, not all of these are actual
How promising is the idea of stem cells for MS? I have been working slowly as time permits on a piece more specifically about hematopoietic stem cell transplantation (HSCT) for MS. Two new pieces caught my eye on this topic so I’ll start with those. Stem cells for MS NurOwn Found Safe, Shows Promise in
Weekly reads: stem cells for MS, blood origins, iPSCs Read More »
An FDA FOIA dump of text messages of former Commissioner Stephen Hahn suggests that a Texas regenerative firm called Direct Biologics benefited from political pressure on him in mid-2020. Then he was asked again to help in early 2021. This was shortly before he resigned at the start of the Biden Administration. The push came from
FDA leader Stephen Hahn was pressured to aid Texas firm Direct Biologics Read More »
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
I’ve been following the stem cells for COVID arena for more than two years. During this time researchers have launched scores of trials. A few have been published including a new one. It’s been a wild ride that at times has included politics and an odd cast of characters. There was Rick Perry and also Rudy Guiliani getting
A close look at new stem cells for COVID trial pub Read More »
Cloning is one of those topics that both fascinates and kind of scares people, especially the idea of duplicating people. I regularly cover the topic here on The Niche because stem cell technologies are involved. Also, one form of the process sometimes called “therapeutic cloning” involves embryonic stem cells. Duplicating mammals has now long been
Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees Read More »